Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Taiwan Bio Therapeutics's Enterprise Value is NT$2,557.3 Mil.
Taiwan Bio Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-300.4 Mil. Therefore, Taiwan Bio Therapeutics's EV-to-FCF for today is -8.51.
The historical rank and industry rank for Taiwan Bio Therapeutics's EV-to-FCF or its related term are showing as below:
ROCO:6892'
s EV-to-FCF Range Over the Past 10 Years
Min: -34.41 Med: -10.25 Max: -6.11
Current: -8.53
During the past 7 years, the highest EV-to-FCF of Taiwan Bio Therapeutics was -6.11. The lowest was -34.41. And the median was -10.25.
ROCO:6892's EV-to-FCF is ranked worse than 100% of 334
companies
in the Biotechnology industry
Industry Median: 15.69
vs ROCO:6892: -8.53
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Taiwan Bio Therapeutics (ROCO:6892) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Taiwan Bio Therapeutics's PE Ratio (TTM) for today is calculated as:
Taiwan Bio Therapeutics's share price for today is NT$26.90.
Taiwan Bio Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-5.047.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6892 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Taiwan Bio Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiwan Bio Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Taiwan Bio Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Taiwan Bio Therapeutics's EV-to-FCF falls into.
Taiwan Bio Therapeutics's current Enterprise Value is NT$2,557.3 Mil.
Taiwan Bio Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-300.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiwan Bio Therapeutics (ROCO:6892) has a EV-to-FCF of -8.51 as of Jul. 16, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Taiwan Bio Therapeutics and its competitors. According to the industry distribution chart, Taiwan Bio Therapeutics ranks #999999 out of 334 companies in the Biotechnology industry.
Is Taiwan Bio Therapeutics' EV-to-FCF too high?
Taiwan Bio Therapeutics' current EV-to-FCF is -8.51. Based on the distribution chart, Taiwan Bio Therapeutics ranks #999999 out of 334 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Taiwan Bio Therapeutics has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Taiwan Bio Therapeutics' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Taiwan Bio Therapeutics ranks #999999 out of 334 companies for EV-to-FCF. This places Taiwan Bio Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 15.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.69, based on 334 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Taiwan Bio Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiwan Bio Therapeutics's current EV-to-FCF is -8.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Bio Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Bio Therapeutics (ROCO:6892) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$14.66, compared to a current price of NT$26.90 — trading 83.5% above its estimated fair value. The current EV-to-FCF is -8.51. Taiwan Bio Therapeutics' overall GF Score™ is 22/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Taiwan Bio Therapeutics (ROCO:6892), the current EV-to-FCF is -8.51 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiwan Bio Therapeutics (ROCO:6892) Overvalued in 2026?
Based on GuruFocus' analysis, Taiwan Bio Therapeutics stock appears to be overvalued.
The current stock price of NT$26.90 is trading 83.5% above its estimated GF Value™ of NT$14.66.
GuruFocus considers Taiwan Bio Therapeutics to be Significantly Overvalued.
Key valuation signals for ROCO:6892:
EV-to-FCF: -8.51
GF Value™: NT$14.66 vs. price of NT$26.90 (83.5% above fair value)
No single metric tells the full story. See the ROCO:6892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiwan Bio Therapeutics Inc is a regenerative medicine company specializing in the development of new genetically modified cell drugs. It is providing commissioned development and manufacturing (CDMO/CMO) services and inspection, analysis and development services for cellular medical products.
22GF Score
Get the complete analysis for ROCO:6892
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6892 has been successfully added to your 
